The French government will take a stake in Sanofi's consumer healthcare division to mitigate backlash over fears of job losses resulting from a potential sale to US private equity.
Sanofi’s decision to enter exclusive talks with Clayton, Dubilier & Rice about selling a 50% stake in Opella highlighted concerns regarding French jobs and control over essential medicines.
Bpifrance's involvement, with a 2% stake contingent on the deal, aims to ensure that investments, production, and employment linked to Opella are maintained in France.
Antoine Armand emphasized that the government has secured guarantees for the maintenance and development of Opella, assuring that job security and production levels will not be compromised.
Collection
[
|
...
]